Nezallix (Azelastine Hydrochloride, Fluticasone Propionate)

Azelastine blocks H1 histamine receptors, preventing the early allergic response, while fluticasone binds glucocorticoid receptors to suppress inflammatory cytokine production and reduce nasal mucosal swelling. Together they control both immediate and delayed allergic reactions.

The exact dosing regimen is determined by the prescribing clinician. Typically, the product is administered as one or two sprays per nostril once daily, but the prescriber will set the appropriate dose based on the patient’s age, severity of symptoms, and response to therapy.

Safety data for Nezallix in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing women.

To request Nezallix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nezallix combines an antihistamine (azelastine) with a corticosteroid (fluticasone), offering both rapid symptom relief and anti‑inflammatory control. Compared with single‑agent sprays such as olopatadine (antihistamine only) or mometasone (corticosteroid only), Nezallix may provide broader symptom coverage, though choice depends on individual response, tolerability and physician preference.

Nezallix should be stored at room temperature, below 25 °C, in its original packaging. Protect the bottle from moisture and direct sunlight. Do not freeze the product, and keep the spray tip clean to maintain dose accuracy.

Nezallix is delivered as a nasal spray. The user gently blows the nose, tilts the head slightly forward, inserts the nozzle into one nostril, and presses the pump while breathing in gently through the nose. The process is repeated in the other nostril if prescribed.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, vision changes or cataract formation with prolonged use, adrenal suppression from systemic corticosteroid absorption, and opportunistic infections like fungal sinusitis. Patients should seek immediate medical attention if they experience any of these symptoms.

Nezallix is contraindicated in individuals with known hypersensitivity to azelastine, fluticasone, or any component of the formulation. It should also be avoided in patients with recent nasal surgery or trauma, and in those using other intranasal corticosteroids without medical supervision.